is a law review article about the private militia movement. It was published in 1995 by the UIC John Marshall Law Review.
is an article by members of the FDA scientific advisory committee that recommended that the FDA reject approval of Aducanumab [Ix4] until further study is completed. It was published on May 5th, 2021. The FDA later approved the drug on June 7th, 2021.
is an article about the decision of the FDA to approve an experimental Alzheimer drug, Aducanumab, for use despite opposition from the scientific community. It was published by the New York Times on June 7th, 2021, the day of the decision by the FDA. It was authored by Pam Belluck and Rebecca Robbins. It raises the over-arching question of whether patient need or scientific rigor should determine the approval of experimental medicies [FxB].
is a paper which analyzes the strategic implications of Jewish settlement in the Sheikh Jarrah neighborhood for the State of Israel. It was published by the Jerusalem Institute for Policy Research in 2010. It was written by Prof. Yitzhak Reiter and Dr. Lior Lehrs.
is a document which explains how the company behind Idealogs and the Idealogs Annotator browser extension deals with your Personal Information.
Subject
-
updated 2 years, 4 months ago
is an academic article analyzing the results of recent clinical trials for the Alzheimer drug aducanumab (ADU). It was published by Alzheimer’s & Dementia, the Journal of the Alzheimer’s Association on November 1st, 2020. It was authored by David S. Knopman, David T. Jones, and Michael D. Greicius. It argues that there is currently insufficient evidence in support of its use [Ix4], and that a new phase III trial is required.
is a reference for frequently asked questions about the Idealogs project
Subject
-
updated 2 years, 10 months ago
is an explanation of the four types of articles in a synesiary.
Subject
-
updated 2 years, 9 months ago
is an article about Alzheimer’s and the amyloid hypothesis, a theory which seeks to explain the underlying cause of Alzheimer’s [Fx8]. It was written in the context of the FDA’s controversial [FxB] decision to approve Aducanumab, a new, experimental drug for the treatment of Alzheimer’s. It was written by Laurie McGinley and published by The Washington Post on July 5th, 2021.
Help
- The front page of Idealogs contains a ranked list of writings, statements, questions on all subjects.
- The feed is searchable.
- To query for recent writings about Spelunking, search Spelunking,. The ',' at the end restricts your query to writings only.
- For statements, use "." (e.g. Spelunking.).
- For questions, use "?" (e.g. Spelunking?).
- For subjects, use ";" (e.g. Spelunking;).
